Journal of Endocrinological Investigation

, Volume 26, Issue 5, pp 453–457 | Cite as

Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome

  • Marco MinettoEmail author
  • A. Dovio
  • M. Ventura
  • S. Cappia
  • F. Daffara
  • M. Terzolo
  • A. Angeli
Case Report


Pheochromocytomas are tumors able to produce catecholamines and a variety of biologically active neuropeptides. We report the case of a 36-yr-old female patient with pheochromocytoma exhibiting headache, intermittent fever, thrombocytosis, and marked inflammatory signs. Nonsteroidal anti-inflammatory drugs were ineffective in lowering the body temperature, while a corticosteroid agent obtained excellent results. IL-6 was found elevated (20 pg/ml); it fell to 4.5 pg/ml 3 weeks after the adrenalectomy, in parallel to normalization of other laboratory data. The interleukin-6 (IL-6) over-production can either be ascribed directly to the tumor (as confirmed by immunohistochemistry) or indirectly accounted for by tumoral production, as a consequence of the high levels of circulating norepinephrine. To our knowledge, our paper represents the 6th case report of IL-6 secreting pheochromocytoma associated with clinical markers of inflammatory response.


Pheochromocytoma catecholamines cytokines interleukin-6 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forman B.H. ACTH-secreting pheochromocytoma. N. Engl. J. Med. 1979, 301: 1399.PubMedGoogle Scholar
  2. 2.
    White A., Ray D.W., Talbot A., Abraham P., Thody A.J., Bevan J.S. Cushing’s syndrome due to phaeochromocytoma secreting the precursors of adrenocorticotropin. J. Clin. Endocrinol. Metab. 2000, 85: 4771–4775.PubMedGoogle Scholar
  3. 3.
    Venihaki M., Gravanis A., Margioris A.N. KAT45 human pheochromocytoma cell line. A new model for the in vitro study of neuro-immuno-hormonal interactions. Ann. N. Y. Acad. Sci. 1998, 840: 425–433.PubMedCrossRefGoogle Scholar
  4. 4.
    Boccara G., Mann C., Guillon G. Secretion of vasopressin from a human pheochromocytoma. Ann. Intern. Med. 1998, 128: 1049.PubMedCrossRefGoogle Scholar
  5. 5.
    Goumon Y., Zhu W., Weeks B.S., et al. Identification of morphine in the adrenal medullary chromaffin PC-12 cell line. Brain Res. Mol. Brain Res. 2000, 81: 177–180.PubMedCrossRefGoogle Scholar
  6. 6.
    Minamino N., Kangawa K., Matsua H. Adrenomedullin: a new peptidergic regulator of the vascular function. Clin. Hemorheol. Microcirc. 2000, 23: 95–102.PubMedGoogle Scholar
  7. 7.
    Saida K., Uchide T., Usui A., et al. The endothelin-2/vasoactive intestinal contractor gene: expression and promoter activity in PC12 rat pheochromocytoma cells. J. Cardiovasc. Pharmacol. 2000, 36: S9–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Takahashi K., Totsune K., Murakami O., et al. Expression of melanin-concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma, ganglioneuroblastoma, and neuroblastoma. J. Clin. Endocrinol. Metab. 2001, 86: 369–374.PubMedGoogle Scholar
  9. 9.
    Ohji H., Sasagawa I., Iciyanagi O., Suzuki Y., Nakada T. Tumour angiogenesis and Ki-67 expression in phaeochromocytoma. B.J.U. Int. 2001, 87: 381–385.CrossRefGoogle Scholar
  10. 10.
    Drenou B., Le Tulzo Y., Caulet-Maugendre S., et al. Pheochromocytoma and secondary erythrocytosis: role of tumour erythropoietin secretion. Nouv. Rev. Fr. Hematol. 1995, 37: 197–199.PubMedGoogle Scholar
  11. 11.
    Rezkalla M.A., Rizk S.N., Ryan J.J. Pheochromocytoma associated with polycythemia: case report. S. D. J. Med. 1995, 48: 349–351.PubMedGoogle Scholar
  12. 12.
    Alheim K., Andersson C., Tingsborg S., Ziolkowska M., Schultzberg M., Bartfai T. Interleukin-1 expression is inducible by nerve growth factor in PC12 pheochromocytoma cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88: 9302–9306.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Bornstein S.R., Ehrhart-Bornstein M., Gonzalez-Hernandez J., Schroder S., Scherbaum W.A. Expression of interleukin- 1 in human pheochromocytoma. J. Endocrinol. Invest. 1996, 19: 693–698.PubMedCrossRefGoogle Scholar
  14. 14.
    Alheim K., McDowell T.L., Symons J.A., Duff G.W., Bartfai T. An AP-1 site is involved in the NGF induction of IL-1 alpha in PC12 cells. Neurochem. Int. 1996, 29: 487–496.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu M.T., Huang H.M., Jeng K.C., Ou S.C., Kuo J.S. Induction of cytokine genes and IL-1alpha by chemical hypoxia in PC12 cells. Life Sci. 2000, 67: 2147–2157.PubMedCrossRefGoogle Scholar
  16. 16.
    Fukumoto S., Matsumoto T., Harada S., Fujisaki J., Kawano M., Ogata E. Pheochromocytoma with pyrexia and marked inflammatory signs: a paraneoplastic syndrome with possible relation to interleukin-6 production. J. Clin. Endocrinol. Metab. 1991, 73: 877–881.PubMedCrossRefGoogle Scholar
  17. 17.
    Suzuki K., Miyashita A., Inoue Y., et al. Interleukin-6 producing pheochromocytoma. Acta Haematol. 1991, 85: 217–219.PubMedCrossRefGoogle Scholar
  18. 18.
    Takagi M., Egawa T., Motomura T., et al. Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Clin. Endocrinol. 1997, 46: 507–509.CrossRefGoogle Scholar
  19. 19.
    Salahuddin A, Rohr-Kirchgraber T, Shekar R, West B, Loewenstein J. Interleukin-6 in the fever and multiorgan crisis of pheochromocytoma. Scand. J. Infect. Dis. 1997, 29: 640–642.PubMedCrossRefGoogle Scholar
  20. 20.
    Shimizu C., Kubo M., Takano K., et al. Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs. Clin. Endocrinol. (Oxf.) 2001, 54: 405–410.CrossRefGoogle Scholar
  21. 21.
    Marz P., Gadient R.A., Otten U. Expression of interleukin- 6 receptor (IL-6R) and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by tumor necrosis factor alpha (TNF-alpha). Brain Res. 1996, 706: 71–79.PubMedCrossRefGoogle Scholar
  22. 22.
    Tirone F., Shooter E.M. Early gene regulation by nerve growth factor in PC12 cells: induction of an interferon-related gene. Proc. Natl. Acad. Sci. U.S.A. 1989, 86: 2088–2092.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Tsigos C., Papanicolaou D.A., Defensor R., Miiadis C.S., Kyrou I., Chrousos G.P. Dose Effects of Recombinant Human Interleukin-6 on Pituitary Hormone Secretion and Energy Expenditure. Neuroendocrinology 1997, 66: 54–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Papanicolaou D.A., Vgontzas A.N. Editorial: Interleukin-6: The Endocrine Cytokine. J. Clin. Endocrinol. Metab. 2000, 85: 1331–1333.PubMedCrossRefGoogle Scholar
  25. 25.
    Chesnokova V., Melmed S. Minireview: Neuro-Immuno- Endocrine Modulation of the Hypothalamic-Pituitary- Adrenal Axis by gp130 Signaling Molecles. Endocrinology 2002, 143: 1571–1574.PubMedCrossRefGoogle Scholar
  26. 26.
    Bastard J.P., Maachi M., Van Nhieu J.T., et al. Adipose Tissue IL-6Content Correlates with Resistance to Insulin Activation of Glucose Uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 2002, 87: 2084–2089.PubMedCrossRefGoogle Scholar
  27. 27.
    Vgontzas A.N., Papanicolaou D.A., Bixler E.O., et al. Circadian Interleukin-6 Secretion and Quantità and Depth of Sleep. J. Clin. Endocrinol. Metab. 1999, 84: 2603–2607.PubMedCrossRefGoogle Scholar
  28. 28.
    Tamura T., Udagawa N., Takahashi N., et al. Soluble interleukin- 6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. U.S.A. 1993, 90: 11924–11928.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Path G., Bornstein S.R., Ehrhart-Bornstein M., Scherbaum W.A. Interleukin-6 receptor in the human adrenal gland: Expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 1997, 82: 2343–2349.PubMedGoogle Scholar
  30. 30.
    Gonzalez-Hernandez J.A., Bornstein S.R., Ehrhart-Bornstein M., Spath-Schwalbe E., Jirikowski G., Scherbaum W.A. Interleukin-6 messenger ribonucleic acid expression in human adrenal gland in vivo: New clue to a paracrine or autocrine regulation of adrenal function. J. Clin. Endocrinol. Metab. 1994, 79: 1492–1497.PubMedGoogle Scholar
  31. 31.
    Montero-Julian F.A. The soluble IL-6 receptors: serum levels and biological function. Cell Mol Biol 2001, 47: 583–597.PubMedGoogle Scholar
  32. 32.
    Ray A., Zhang D.H., Siegel M.D., Ray P. Regulation of interleukin- 6 gene expression by steroids. Ann. N.Y. Acad. Sci. 1995, 762: 79–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Hirano T., Taga T., Nakano N., et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc. Natl. Acad. Sci. U.S.A. 1985, 82: 5490–5494.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Hirano T., Yasukawa K., Harada H., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324: 73–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Takizawa H., Narisawa R., Asakura H. Jejunal invasion of pheochromocytoma pathologically confirmed by endoscopic biopsy. Am. J. Med. Sci. 1999, 317: 63–66.PubMedCrossRefGoogle Scholar
  36. 36.
    Sakai C., Takagi T., Oguro M., Wakatsuki S., Kuwahara T. Malignant pheochromocytoma accompanied by microangiopathic hemolytic anemia: a case report. Jpn. J. Clin. Oncol. 1994, 24: 171–174.PubMedGoogle Scholar
  37. 37.
    Johnson C.S., Cook C.A., Furmanski P. in vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO). Exp. Hematol. 1990, 18: 109–113.PubMedGoogle Scholar
  38. 38.
    Fuchs D., Hausen A., Reibnegger G., et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur. J. Haematol. 1991, 46: 65–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Means R.T. Jr., Dessypris E.N., Krantz S.B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J. Cell. Physiol. 1992, 150: 59–64.PubMedCrossRefGoogle Scholar
  40. 40.
    Jovcic G., Ivanovic Z., Biljanovic-Paunovic L., Bugarski D., Stosic-Grujicic S., Milenkovic P. The effect of IL-1 receptor antagonist on the proliferation of hematopoietic progenitor cells in regenerating bone marrow. Leukemia 1996, 10: 564–569.PubMedGoogle Scholar
  41. 41.
    Allen D.A., Breen C., Yaqoob M.M., Macdougall I.C. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNFalpha. J. Investig. Med. 1999, 47: 204–211.PubMedGoogle Scholar
  42. 42.
    Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol. Dial. Transplant. 1995, 10: S27–30.CrossRefGoogle Scholar
  43. 43.
    Cazzola M., Ponchio L., de Benedetti F., et al. Defective Iron Supply for Erythropoiesis and Adequate Endogenous Erythropoietin Production in the Anemia Associated With Systemic-Onset Juvenile Chronic Arthritis. Blood 1996; 87: 4824–4830.PubMedGoogle Scholar
  44. 44.
    Plouin P.F., Chatellier G., Fofol I., Corvol P. Tumour recurrence and hypertension persistence after successfull phaeochromocytoma operation. Hypertension 1997, 29: 1133–1139.PubMedCrossRefGoogle Scholar
  45. 45.
    Van der Harst E., de Krijger R.R., Bruining H.A., et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur. J. Endocrinol. 2002, 147: 85–94.PubMedCrossRefGoogle Scholar
  46. 46.
    van Gool J., van Vugt H., Helle M., Aarden L.A. The Relation Among Stress, Adrenalin, Interleukin 6 and Acute Phase Proteins in the Rat. Clin. Immunol. Immunopathol. 1990, 57: 200–210.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2003

Authors and Affiliations

  • Marco Minetto
    • 1
    Email author
  • A. Dovio
    • 1
  • M. Ventura
    • 1
  • S. Cappia
    • 2
  • F. Daffara
    • 1
  • M. Terzolo
    • 1
  • A. Angeli
    • 1
  1. 1.Department of clinical and Biological SciencesGeneral Medical ClinicOrbassano (TO)Italy
  2. 2.Pathologic Anatomy S.C.D.OSan Luigi HospitalOrbassano (TO)Italy

Personalised recommendations